BOLD
Audentes Therapeutics, Inc#22 · 2019EPBYearly return
+32%
Peak return
+47%
Max drawdown
-30%
ADR (20 days)
+5.9%
Base
10 days / -13.0%
Prior run
+28%
Breakout volume
63.7x
Pivot
$1.23
Catalyst FDA/Clinical2026-04-17Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual MeetingGlobeNewswire Inc.
Biotech-/Medtech-News mit binaerem Daten-, Zulassungs- oder Studiencharakter.
Healthcare · Healthcare & Biotech
Continue in the full Atlas
Drawing, alerts, replay and the live scanner built on the same criteria are part of WickedDesk. Compare BOLD with the current market directly.